TL;DR: C cautious examination of intrathecal neostigmine alone and in combination with other agents for analgesia is warranted because no unexpected or dangerous side effects occurred and effects in humans are consistent with studies in animals.
Abstract: Background In dogs, sheep, and rats, spinal neostigmine produces analgesia alone and enhances analgesia from alpha 2-adrenergic agonists. This study assesses side effects and analgesia from intrathecal neostigmine in healthy volunteers. Methods After institutional review board approval and informed consent, 28 healthy volunteers were studied. The first 14 volunteers received neostigmine (50-750 micrograms) through a #19.5 spinal needle followed by insertion of a spinal catheter. The remaining 14 volunteers received neostigmine through a #25 or #27 spinal needle without a catheter. Safety measurements included blood pressure, heart rate, oxyhemoglobin saturation, end-tidal carbon dioxide, neurologic evaluation, and computer tests of vigilance and memory. Analgesia in response to ice water immersion was measured. Results Neostigmine (50 micrograms) through the #19.5 needle did not affect any measured variable. Neostigmine (150 micrograms) caused mild nausea, and 500-750 micrograms caused severe nausea and vomiting. Neostigmine (150-750 micrograms) produced subjective leg weakness, decreased deep tendon reflexes, and sedation. The 750-micrograms dose was associated with anxiety, increased blood pressure and heart rate, and decreased end-tidal carbon dioxide. Neostigmine (100-200 micrograms) in saline, injected through a #25 or #27 needle, caused protracted, severe nausea, and vomiting. This did not occur when dextrose was added to neostigmine. Neostigmine by either method of administration reduced visual analog pain scores to immersion of the foot in ice water. Conclusions The incidence and severity of these adverse events from intrathecal neostigmine appears to be affected by dose, method of administration, and baricity of solution. These effects in humans are consistent with studies in animals. Because no unexpected or dangerous side effects occurred, cautious examination of intrathecal neostigmine alone and in combination with other agents for analgesia is warranted.
TL;DR: Variability in lumbosacral CSF volume is the most important factor identified to date that contributes to the variability in the spread of spinal sensory anesthesia.
Abstract: BackgroundInjection of local anesthetic into cerebrospinal fluid (CSF) produces anesthesia of unpredictable extent and duration. Although many factors have been identified that affect the extent of spinal anesthesia, correlations are relatively poor and the extent of spread remains unpredictable. Th
TL;DR: It is demonstrated that low-dose bupivacaine in spinal anaesthesia compromises anaesthetic efficacy (risk of analgesic supplementation: high grade of evidence), despite the benefit of lower maternal side-effects (hypotension, nausea/vomiting: moderate grade ofevidence).
Abstract: Summary Spinal anaesthesia is the preferred anaesthetic technique for elective Caesarean deliveries. Hypotension is the most common side-effect and has both maternal and neonatal consequences. Different strategies have been attempted to prevent spinal-induced hypotension, including the use of low-dose bupivacaine. We conducted a systematic search for randomized controlled trials comparing the efficacy of spinal bupivacaine in low dose (LD ≤8 mg) with conventional dose (CD >8 mg) for elective Caesarean delivery. Thirty-five trials were identified for eligibility assessment, 15 were selected for data extraction, and 12 were finally included in the meta-analysis. We investigated sources of heterogeneity, subgroup analysis, and meta-regression for confounding variables (baricity, intrathecal opioids, lateral vs sitting position, uterine exteriorization, and study population). Sensitivity analysis was performed to test the robustness of the results. In the LD group, the need for analgesic supplementation during surgery was significantly higher [risk ratio (RR)=3.76, 95% confidence interval (95% CI)=2.38–5.92] and the number needed to treat for an additional harmful outcome (NNTH) was 4 (95% CI=2–7). Furthermore, the LD group exhibited a lower risk of hypotension (RR=0.78, 95% CI=0.65–0.93) and nausea/vomiting (RR=0.71, 95% CI=0.55–0.93). Conversion to general anaesthesia occurred only in the LD group (two events). Neonatal outcomes (Apgar score, acid–base status) and clinical quality variables (patient satisfaction, surgical conditions) showed non-significant differences between LD and CD. This meta-analysis demonstrates that low-dose bupivacaine in spinal anaesthesia compromises anaesthetic efficacy (risk of analgesic supplementation: high grade of evidence), despite the benefit of lower maternal side-effects (hypotension, nausea/vomiting: moderate grade of evidence).
TL;DR: In a double-blind study of spinal anaesthesia with 0.5% bupivacaine 3 ml with no glucose, 5% glucose or 8% glucose all three solutions gave consistently good nerve blocks, whereas the plain solution seldom affected the thoracic nerves.
Abstract: In a double-blind study of spinal anaesthesia with 0.5% bupivacaine 3 ml with no glucose, 5% glucose or 8% glucose all three solutions gave consistently good nerve blocks. The hyperbaric solutions (5% and 8% glucose) produced a greater cephalad spread and were suitable for lower abdominal surgery, whereas the plain solution (no glucose) seldom affected the thoracic nerves. Cardiovascular changes were more marked with the hyperbaric solutions but only necessitated treatment on two occasions. The duration of block was not affected by baricity and was in the range 140–160 min.
TL;DR: The density of local anaesthetics decreases with increasing temperature and increases in a linear fashion with the addition of dextrose.
Abstract: Background Spread of intrathecal local anaesthetics is determined principally by baricity and position of the patient. Hypobaric solutions of bupivacaine are characterized by an unpredictable spread of sensory block whereas addition of dextrose 80 mg ml−1 provides a predictable spread but to high thoracic levels. In contrast, dextrose concentrations between 8 and 30 mg ml−1 have shown reliable and consistent spread for surgery. Hence, the aim of this study was to determine the density of bupivacaine, levobupivacaine, and ropivacaine with and without dextrose at both 23 and 37°C before embarking on clinical studies. Methods Density (mg ml−1) was measured using the method of mechanical oscillation resonance, accurate to five decimal places on 1250 samples. 500 density measurements were performed in a randomized, blind fashion at 23 and 37°C on 10 plain solutions of bupivacaine (2.5, 5, and 7.5 mg ml−1) levobupivacaine (2.5, 5, and 7.5 mg ml−1) and ropivacaine (2, 5, 7.5, and 10 mg ml−1). Following this, 750 density measurements were taken at 23 and 37°C on the 5 mg ml−1 solutions of bupivacaine, levobupivacaine, and ropivacaine with added dextrose (10, 20, 30, 50, and 80 mg ml−1). Results There was a linear relationship between density and dextrose concentration for all three local anaesthetics (R2=0.99) at 23 and 37°C. The mean density of levobupivacaine 5 mg ml−1 was significantly greater than the densities of bupivacaine 5 mg ml−1 and ropivacaine 5 mg ml−1 after adjusting for dextrose concentration using analysis of covariance. This difference existed both at 23 and 37°C. The mean (sd) density of levobupivacaine 7.5 mg ml−1 was 1.00056 (0.00003) mg ml−1, the lower 0.5% percentile (1.00047 mg ml−1) lying above the upper limit of hypobaricity for all patient groups. Conclusions The density of local anaesthetics decreases with increasing temperature and increases in a linear fashion with the addition of dextrose. Levobupivacaine 5 mg ml−1 has a significantly higher density compared with bupivacaine 5 mg ml−1 and ropivacaine 5 mg ml−1 at 23 and 37°C both with and without dextrose. Levobupivacaine 7.5 mg ml−1 is an isobaric solution within all patient groups at 37°C.